MEDTOX Scientific (Nasdaq: MTOX ) reported earnings on July 12. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), MEDTOX Scientific met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share dropped.
Margins shrank across the board.
MEDTOX Scientific logged revenue of $30.0 million. The two analysts polled by S&P Capital IQ expected revenue of $30.3 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $27.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.17. The two earnings estimates compiled by S&P Capital IQ predicted $0.21 per share. GAAP EPS of $0.14 for Q2 were 13% lower than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.1%, 120 basis points worse than the prior-year quarter. Operating margin was 6.3%, 150 basis points worse than the prior-year quarter. Net margin was 4.1%, 90 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $30.6 million. On the bottom line, the average EPS estimate is $0.23.
Next year's average estimate for revenue is $119.3 million. The average EPS estimate is $0.78.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 154 members out of 163 rating the stock outperform, and nine members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give MEDTOX Scientific a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDTOX Scientific is underperform, with an average price target of $27.00.
Over the decades, small-cap stocks, like MEDTOX Scientific have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add MEDTOX Scientific to My Watchlist.